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Models of disease susceptibility in multiple sclerosis (MS) often assume a dominant action for theHLA-DRB1*1501
allele and its associated haplotype (DRB1*1501-DQB1*0602 or DR2). A robust and phenotypically well-char-
acterized MS data set was used to explore this model in more detail. A dose effect of HLA-DR2 haplotypes on
MS susceptibility was revealed. This observation suggests that, in addition to the role of HLA-DR2 in MS, two
copies of a susceptibility haplotype further increase disease risk. Second, we report that DR2 haplotypes modify
disease expression. There is a paucity of benign MS and an increase of severe MS in individuals homozygous for
DR2. Concepts of the molecular mechanisms that underlie linkage and association of the human leukocyte antigen
(HLA) region to MS need to be revised to accommodate these data.
The association of multiple sclerosis (MS [MIM126200])
with the human leukocyte antigen (HLA) region has
been known for more than a quarter of a century (Ber-
trams and Kuwert 1972; Naito et al. 1972). A specific
association with the DRB1*1501 molecule and its as-
sociated haplotype (DRB1*1501-DQB1*0602 or DR2
[MIM 142857 and MIM 604305, respectively]) is pre-
sent in most populations with MS (Haines et al. 1998;
Rubio et al. 2002); the only exceptions are an apparent
association with DR3 and DR4 in patients with MS
from Sardinia (Marrosu et al. 2002) and, perhaps, no
DR2 association in some Asian populations who have
a restricted form of MS, termed “neuromyelitis optica,”
selectively affecting optic nerve and spinal cord myelin
(Kira et al. 1996). Whole-genome mapping studies pro-
vide additional support for the presence of an MS sus-
ceptibility gene located within chromosome 6p21 (Haines
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et al. 1996, 1998). However, fine-mapping studies have
not settled whether the effect is explained by the DRB1
gene itself; by variation at another closely linked gene
within the class 2 HLA region in very high linkage
disequilibrium (LD) with DRB1*1501, such as DQB1*
0602; or by some other nearby gene in LD. Identification
of the true predisposing gene or genes has been made
more complex by extensive LD across the HLA region
and by the presence of 1240 genes within this superlocus,
many of which have roles in immune function and are
thus plausible MS candidates.
Linkage to the HLA region plus a specific association
with theDR2 haplotype suggests thatDRB1*1501-bear-
ing haplotypes confer an effect on MS susceptibility that
is distinct from that of other major histocompatibility
(MHC) haplotypes. In support of this hypothesis, no
evidence for linkage to 6p21 could be discerned in fam-
ilies who did not carry DR2 (Chataway et al. 1998;
Haines et al. 1998; Barcellos et al. 2002). Locus hetero-
geneity may not be present in all populations, however,
underscoring the complex genetic nature of this disease
(Ligers et al. 2001).
To better delineate the role of the HLA locus in MS
and, in particular, the risk and phenotype associatedwith
theDR2 homozygous state, we analyzed a large and well-
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Table 1
Disease Course and Severity Phenotypes in Patients with MS
Clinical Phenotype N (%)
RR 487 (62.8)
SP 235 (30.3)
Othera 53 (6.8)
Mild MS: EDSS !3 after 10 yearsb 71 (14.8)
Mild MS: EDSS !3 after 15 yearsb 40 (11.9)
Severe MS: EDSS 16 in 10 yearsc 35 (10.8)
NOTE.—A total of 808 patients with clinically definite MS was
studied. Complete clinical data were available for 195% of
individuals.
a PP and RP clinical subtypes.
b Classifications of benign or mild MS. Patients in this group
can walk normally or have mild gait disability only after 10 or
15 years from disease onset.
c Patients in this group require bilateral assistance to walk or
are wheelchair dependent in 10 years from disease onset. The
percentages shown for mild and severe phenotypes reflect the
proportion of individuals in patient groups restricted by disease
duration; for example, for mildMS, patients with disease duration
of 10 or 15 years only are included ( and ,np 480 np 335
respectively), and, for severe MS, only patients with disease du-
ration of 10 years are included ( ).np 323
Figure 1 Proportion of affected and unaffected individuals
within 549 families with MS grouped by HLA-DR2 genotypes. The
data set contained 2,382 individuals comprising 808 patients withMS
and 1,574 unaffected family members. A total of 26.9% ( )np 319
DRX/DRX and 38.7% ( )DR2/DRX individuals were affected,np 395
in contrast to 52.8% ( ) DR2/DR2 individuals, demonstratingnp 94
a dose effect of HLA-DR2 on susceptibility.
characterized family-based cohort of 549 families prone
to MS (187 multicase and 362 single affected, or “sin-
gleton”) comprising 2,382 individuals, including 808 af-
fected individuals and 1,574 unaffected familymembers.
Diagnostic criteria, ascertainment protocols, and clinical
and demographic characteristics of the multicase fami-
lies are summarized elsewhere (Goodkin et al. 1991;
Multiple Sclerosis Genetics Group [MSG Group] 1998;
Haines et al. 1998; Barcellos et al. 2002). Singleton fam-
ilies were collected using identical ascertainment criteria;
these families were required to have an affected proband
with either two living parents or at least one unaffected
sibling. The singleton family ascertainment was coor-
dinated at the University of California San Francisco in
collaboration with a network of specialized clinical sites
throughout the United States.
All known ancestors were non-Hispanic whites of Eu-
ropean descent. Complete clinical data were available
for 96.0% of patients. For affected individuals, the fe-
male-to-male ratio was 3.0:1. The overall mean age at
onset was years, and mean disease duration30.1 8.8
was years. Age at onset was defined as the14.6 10.2
first episode of neurological dysfunction suggestive of
demyelinating disease (Doolittle et al. 1990; Barcellos et
al. 2000). Disease course was recorded for patients at
entry into study as either relapsing remitting (RR), sec-
ondary progressive (SP), primary progressive (PP), or re-
lapsing progressive (RP). Disability was also assessed at
entry with the Expanded Disability Status Scale (EDSS)
(Kurtzke 1983). “Mild” (benign) and “severe” disease
patient classifications were based on EDSS scores that
were maintained over or achieved within designated time
intervals were also used in the present study (see table 1
for details). The appropriate institutional review boards
approved all studies, and informed consent was obtained
from all participants.
HLA typing forDRB1 andDQB1 loci was performed
using a nonradioactive PCR-based sequence-specific ol-
igonucleotide probe reverse line-blot assay (PCR-SSOP)
(Dynal). Generation of all genotypes was performed
blind to pedigree structure and clinical status of the in-
dividual. PEDCHECK (O’Connell andWeeks 1998) was
used to check for Mendelian consistency within all fam-
ilies withMS. Family-based association testing for alleles
at the HLA-DR locus was performed for the combined
family data set, using the “sum” option of the pedigree
disequilibrium test (PDT v.3.11 [available at the Duke
University Center for Human Genetics Web site];Martin
et al. 2000, 2001). The PDT can utilize genetic data from
related nuclear families and discordant sibships within
extended pedigrees. A strong association withHLA-DR
overall ( ) and with the DR2 haplotype10P ! 1.0# 10
specifically ( ) was observed, as reported11P ! 1.0# 10
elsewhere, in a subset of this population (Barcellos et al.
2002). No evidence for excess transmission of otherDR
alleles to affected individuals was present.
All patients and unaffected family members were
stratified byHLA-DR genotype (DR2/DR2,DR2/DRX,
and DRX/DRX, where X denotes other DR alleles) to
test for effects ofHLA-DR2 dose on disease susceptibility.
An effect ofHLA-DR2 copy number on disease risk was
suggested by the observed difference in proportion of
affected individuals within eachHLA-DR genotypic cat-
egory (fig. 1). A total of 52.8% ofDR2/DR2 individuals
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Table 2
OR for HLA-DR Genotypes in Patients with MS Compared with Unaffected Family Members
TEST GROUP REFERENCEa
OR (95% CI)
All Families Multicase Only Singleton Only
DR2/DR2 DRX/DRX 6.7 (4.2–10.7)b 6.1 (3.4–11.0)b 7.9 (3.7–17.0)b
DR2/DRX DRX/DRX 2.7 (2.1–3.6)b 2.6 (1.8–3.7)b 3.0 (2.0–4.5)b
DR2/DR2 DR2/DRX 2.5 (1.7–3.7)c 2.4 (1.4–3.9)d 2.7 (1.4–5.1)e
NOTE.—The analyses include all affected and unaffected individuals from families with multicase ( ) and singleton (np 187 np
) MS (total individuals; affected and 1,574 unaffected individuals).362 np 2,382 np 808
a The DRX group refers to all other non-DR2 (DRB1*1501–DQB1*0602) alleles. All analyses were performed using conditional
logistic regression modeling and controlling for sex as implemented in PROC PHREG (SAS v. 8.2). All individuals were stratified by
family for analyses. Unaffected family members included all parents and siblings of affected individuals.
b .6P ! 10
c .5P ! 10
d .3P ! 10
e .P ! .01
Table 3
Relative Penetrance Values for HLA-DR Genotypes
Index Cases from DR2/DR2 DR2/DRX
All familiesa 11.8 3.8
Singleton families onlyb 9.1 2.9
Multicase families onlyc 20.0 6.7
NOTE.—Control genotype frequencies for P/C ratios were derived
using nontransmitted alleles from singleton families assuming Hardy
Weinberg proportions (Thomson 1995) (DR2 orDRB1*1501-DQB1*
0602: ). Nontransmitted allele frequencies derived using ad-fp 0.122
ditional trios from multicase families (one per family) were similar
(data not shown). All relative penetrance values were normalized to
a value of 1 for the reference DRX/DRX genotype.
a .np 549
b .np 362
c .np 187
was affected, in contrast to 37.8% of DR2/DRX and
26.9% of DRX/DRX individuals. Conditional logistic
regression modeling was then used to evaluate the effect
of DR genotype on disease risk in the family data set.
For these analyses, carriers of two (DR2/DR2) and one
(DR2/DRX) DR2 haplotypes were compared with
DRX/DRX individuals. Significant effects on disease risk
were observed for both DR2/DR2 and DR2/DRX geno-
types in all families (odds ratio ,[OR]p 6.7 P ! 1.0#
and , ), as well as multi-6 610 ORp 2.7 P ! 1.0# 10
case and singleton families considered separately (table
2). Significant results were also obtained whenDR2/DR2
individuals were compared with individuals with DR2/
DRX genotypes (table 2), indicating that two copies of
DR2 confer a greater risk compared with one copy
( , , ,5ORp 2.5 P ! 1.0# 10 ORp 2.4 P ! 1.0#
, and , for all families, multicase,310 ORp 2.7 P ! .01
and singleton families, respectively).When analyseswere
restricted to sibships only, or just one single discordant
sib pair selected from each family, the results were very
similar (data not shown).
A second approach, a modification of the PDT, was
also used to examine HLA-DR genotypic associations
in the combined family data set. This test, the geno-PDT,
is also applicable to nuclear family or extended pedigree
data and can be used to test any specific genotype, or a
global statistic can be computed to test all genotypes
simultaneously. The PDT and geno-PDT both test the
same null hypotheses but can have different powers, de-
pending on the genetic model. Significant evidence for
excess transmission of both DR2/DR2 and DR2/DRX
genotypes was observed in the families with MS (P !
and , respectively; data not shown),5.01 P ! 1.0# 10
providing further support for both genotypes as disease
risk factors.
Maximum-likelihood estimates of the relative pene-
trance values for MS-associated DR2/DR2 and DR2/
DRX genotypes were determined using the ratio of the
observed genotype frequency in patients over the fre-
quency in controls (or P/C ratio), as described elsewhere
(McWeeney and Thomson 2000). Control genotype fre-
quency estimates were derived under the expectation of
Hardy-Weinberg equilibrium, using nontransmitted (or
non-MS) HLA-DR allele frequencies in the singleton
families with MS (Thomson 1995). The penetrance val-
ues shown in table 3 have been normalized using a value
of 1 for the reference DRX/DRX genotype. The results
suggest that the relative penetrance for the DR2 homo-
zygous genotype is at least twice as large as that for the
DR2/DRX genotype in all families and in both multicase
and singleton families considered separately.
The effect of HLA-DR2 genotype on clinical pheno-
types, including age at onset and disease course and se-
verity, was tested in the patient data set, using linear and
logistic models estimated by generalized estimating equa-
tions (Liang and Zeger 1986; Zeger and Liang 1992),
which take into account any correlation between family
members. The proportions shown in table 1 are derived
from the total number of individuals with a particular
clinical phenotype present within the data set. Although
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Figure 2 A comparison of HLA-DR genotypes for patient sub-
groups of mild and nonmild MS. Analyses were restricted to patients
with disease duration of at least 10 years ( ). P values are fromnp 480
PROC GENMOD (SAS version 8.2), using logistic regression with
correction for familial correlations and adjustment for age at onset
and sex. OR of mild MS for DR2 homozygotes ,(DR2/DR2)p 0.3
95% , . Reference grouppDRX/DRX genotype.CIp 0.1–0.9 P ! .05
When DR2/DR2 individuals were compared with individuals with
DR2/DRX genotype, , 95% , . ThereORp 0.3 CIp 0.1–1.1 P ! .10
was no evidence for increased risk of mildMS phenotype in individuals
carrying just one copy of HLA-DR2 haplotype, , 95%ORp 0.8
, . Because noDR2/DR2 individuals were presentCIp 0.5–1.4 P 1 .10
in analyses of mild MS 15 years from onset, the statistical methods
used above were not appropriate. Therefore, to determine statistical
significance, unrelated mild MS cases were compared to other ran-
domly selected unrelated cases using Fisher’s exact test, as implemented
in PROC FREQ (version 8.2, SAS; ; data not shown). LogisticP ! .01
regression modeling with correction for familial correlations and ad-
justments for age at onset and sex was also used for comparisons of
HLA-DR genotypes in patient subgroups of severe and nonsevere MS
(data not shown). See text for results.
Figure 3 HLA-DR genotype frequencies for all patients (index
cases only, ) and most extreme phenotypes, patients with mildnp 549
(!3 for 15 years) and severe MS. Because no DR2/DR2 individuals
were present in the patient group with mild MS, unrelated mild MS
cases ) were compared with unrelated severe cases ( ),(np 39 np 33
using Fisher’s exact test, as implemented in PROC FREQ (version 8.2,
SAS). The overall difference between genotype distributions for pa-
tients with mild and severe MS was significant ( ); 18.2% ofP ! .01
patients with severe MS were homozygous for HLA-DR2, compared
with 0% in patients with mild MS.
phenotypic categorization results in smaller sample sizes
and a potential loss in statistical power, the increased
clinical homogeneity in these subgroups may also in-
crease the likelihood of detecting specific disease-mod-
ulating genetic effects. In the patient group with mild,
or benign, MS,DR2 homozygotes were significantly less
frequent compared with patients classified as having
nonmild MS (5.4% vs. 13.0%), using the DRX/DRX
genotype as a reference group ( , 95%ORp 0.3 CIp
, ; see fig. 2). Here, “mild MS” was de-0.1–0.9 P ! .05
fined as maintaining an EDSS score of !3 for at least 10
years. When a more stringent definition of “mild MS”
was applied, in which disease duration of at least 15
years was imposed, no DR2 homozygotes were present
in this subgroup. This result was also significant (Fisher’s
exact test, ; see fig. 2 legend for details). BothP ! .01
observations provide strong support for HLA-DR2 as
a disease modifier. Furthermore,DR2 homozygoteswere
observed more frequently in patients with a severe dis-
ease course (those defined as reaching an EDSS score 16
in 10 years) in contrast to patients classified as “non-
severe” (17.1% vs. 10.1%, , 95%ORp 1.8 CIp
; data not shown), though this observation did0.7–5.0
not reach statistical significance ( ).P 1 .10
WhenHLA-DR genotypic proportions for individuals
with either mild or severe disease classifications were
compared with nonmild or nonsevere groups, respec-
tively, the observed effect on disease expression was lim-
ited to those individuals carrying two copies of theHLA-
DR2 haplotype. Using DR2/DRX as a reference group,
trends for association were observed for both mild and
severe phenotypes ( , 95% ,ORp 0.3 CIp 0.1–1.1
and , 95% , ),P ! .10 ORp 2.3 CIp 0.8–6.4 P 1 .10
respectively. There was no evidence for effects of DR2/
DRX, as compared with DRX/DRX, for either clinical
phenotype ( for both mild and severe subgroupsP 1 .40
of MS, respectively; data not shown), suggesting that
one copy of the haplotype may be insufficient for ex-
pression of these disease variants. The difference inDR2/
DR2 genotype frequencies between the two most ex-
treme clinical phenotypes, mild (disease duration of at
least 15 years) and severe, was striking (Fisher’s exact
test, ; see fig. 3 for details), although the resultsP ! .01
must be interpreted cautiously because of small sample
sizes. Significant effects were not present for DR2 dose
on disease course (RR, SP, and PP), and no DR2-de-
pendent difference in mean age at onset was detected.
The use of a well-characterized data set of white MS-
prone families permitted, for the first time in a large and
prospectively ascertained population, an analysis of dis-
ease risk in individuals homozygous for the MS-asso-
ciated HLA-DR2 haplotype. A dose effect on MS sus-
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ceptibility was revealed. This finding is unexpected,
although it is also supported by a recent meta-analysis
of three small published data sets comprising a total of
35 DR2 homozygous individuals (Rasmussen et al.
2001). Although relative penetrance values forHLA-DR
genotypes derived in the present study also support a
DR2 dose effect for disease risk, the available data do
not distinguish between additive andmultiplicativemod-
els. In experimental models of autoimmune demyelina-
tion, a single copy of a disease-associated MHC haplo-
type, when present in the context of an appropriate
genetic background, is generally sufficient for the in-
duction of susceptibility. Dominantly actingMHC genes
are thought to function via high-affinity binding to cer-
tain self-peptides, which are then efficiently presented to
pathogenic T cells (Todd et al. 1987).
In the case of DRB1*1501, binding and structural
data support a model of the peptide-binding region that
is composed in part of a large hydrophobic pocket dis-
playing high affinity for aromatic amino acids, including
phenylalanine at aa 92 of an immunodominant peptide
(aa 89–96) of the autoantigen myelin basic protein (MBP)
(Valli et al. 1993; Smith et al. 1998). A direct role for
autoimmunity against the aa 89–96 region of MBP in
the pathogenesis of MS is suggested by the findings of
immunodominance of the T-cell response to this peptide
in DRB1*1501-positive individuals (Martin et al. 1990;
Ota et al. 1990), specific activation of these T cells in
the circulation of patients withMS (Allegretta et al. 1990;
Scholz et al. 1998), and presence in MS lesions of T-cell
receptors bearing antigen recognition CDR3 motifs likely
to recognize this peptide (Oksenberg et al. 1993). The
“tight binder” concept and immunodominant peptide
model has been applied to a variety of other autoimmune
diseases in which MHC alleles function as dominantly
acting susceptibility genes (Svejgaard et al. 1983), in-
cluding pemphigus vulgaris (Wucherpfennig et al. 1995).
One model to explain a dose effect of MHC genes on
MS predicts that more than one gene within the MHC
class 2 region, and perhaps beyond this region, contrib-
utes to disease risk. This model has been most fully de-
veloped for rheumatoid arthritis (RA) (Zanelli et al.
2000). Although disease-associated alleles differ between
RA and MS, a dose effect of MHC genes on risk is com-
mon to the two conditions. In RA,DRB genes that encode
a sequence containing a shared epitope—consisting of the
motif Q(or R)K(or R)RRA in the third hypervariable re-
gion of the DRB protein contributing to the antigen bind-
ing properties of the molecule—influence susceptibility
in a dominant manner (Gregersen et al. 1987). The ad-
jacent DQ locus also influences risk but via a different
mechanism, which may involve binding of the shared
epitope itself to DQ, which results in the activation of
protective regulatory T cells (van der Horst-Bruinsma et
al. 1999).
In MS, the observed dose effects might be similarly
explained by a dominantly acting susceptibility gene pre-
sent on DRB1*1501 haplotypes plus the absence of a
protective gene required for the maintenance of periph-
eral tolerance present on non-DRB1*1501 haplotypes.
Loss of protection could conceivably result from a per-
turbation in the balance of Th1 and Th2 cytokines in-
fluenced by other class 2 MHC loci, such as DQ, or by
other genes in the HLA region, such as tumor necrosis
factor (TNF). Because of the tight LD between DRB1*
1501 and DQB1*0602 in whites, it has not been pos-
sible to discern whether DQB1*0602 has any indepen-
dent role in MS (Rubio et al. 2002). With respect to TNF,
DRB1*1501 haplotypes are associated with a promoter
polymorphism in TNF that modulates levels of expres-
sion of this proinflammatory Th1 cytokine (Garcia-Me-
rino et al. 1996). T-cell clones triggered by antigen pre-
sented in the context of DRB1*1501 have also been
reported to display a Th1-biased pattern of cytokine se-
cretion (Zipp et al. 1995). Thus, homozygosity for
DRB1*1501 could influence the outcome of interactions
with MS autoantigenic peptides, by promoting an en-
vironment in which peripheral tolerance is not main-
tained. As an alternative explanation, current data can-
not exclude the possibility that a dose effect of DRB1*
1501 might result simply from higher levels of surface
expression of DRB1*1501 on antigen-presenting cells in
the homozygous state, increasing the likelihood that my-
elin autoantigens will be presented to encephalitogenic T
cells.
The genotype-phenotype correlation revealed that pa-
tients with MS who were homozygous for HLA-DR2
were unlikely to have a benign course and to be at greater
risk for a more severe disease outcome. In contrast to
the observed HLA-DR2 effects on disease susceptibility,
a single copy of theHLA-DR2 haplotype did not appear
to influence mild or severe disease expression. The anal-
yses of HLA-DR2 effects on disease behavior have been
contradictory. Almost all studies have been based on
phenotypic (presence or absence of DR2) rather than
genotypic data and have shown associations with both
favorable and unfavorable outcomes or no association
at all (for review, see Kantarci et al. [2002]). A recent
population-based case-control study showed no differ-
ences inDR2/DR2 genotype frequencies between PPMS
and “bout onset” MS (Weinshenker et al. 1998). Al-
though the numbers of individuals within the mild and
severe phenotypic categories presented here are small,
our results underscore the importance of including ge-
notypic information in analyses of clinical data.
Our observation of a DR2 effect on disease outcome
is also consistent with a model of protection mediated
by DRB1*1501-negative haplotypes and the concept
that a Th1 bias drives an aggressive disease course in
experimental autoimmune demyelination (Powell et al.
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1990) and in humanMS (Beck et al. 1988; Tejada-Simon
et al. 2001). Analogous to MS, in RA, a similar dose
effect of MHC genes on indices of clinical severity, in-
cluding erosive manifestations and rheumatoid factor
production, is clearly present (Weyand et al. 1992; El-
Gabalawy et al. 1999). The proposed model has several
testable implications, including an expectation that my-
elin autoantigen-reactive T-cell clones derived from
DRB1*1501 homozygous individuals should display a
strong Th1 bias and that generation of regulatory T cells
from such individuals might be impaired.
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